Sydney's Chris O'Brien Lifehouse and Royal Prince Alfred Hospital haematology departments manage myeloma and lymphoma patients from across New South Wales requiring Bortezomib-based combination therapy. Bortenat 3.5mg injection vials provide Sydney's oncology pharmacies with WHO-GMP certified Bortezomib at significantly reduced institutional cost compared to brand Velcade.
Sydney's diverse population — including large Chinese, Korean, and South Asian communities among whom haematological malignancies carry specific incidence patterns — accesses world-class cancer care through NSW Health. For institutional procurement teams seeking cost-effective Bortezomib sourcing, Bortenat provides full documentation for PBS and TGA-compliant supply pathways.
Sydney's diverse population — including large Chinese, Korean, and South Asian communities among whom haematological malignancies carry specific incidence patterns — accesses world-class cancer care through NSW Health. For institutional procurement teams seeking cost-effective Bortezomib sourcing, Bortenat provides full documentation for PBS and TGA-compliant supply pathways.
❓ What is the difference between multiple myeloma and amyloidosis — can Bortenat treat both?
Multiple myeloma and AL amyloidosis are both plasma cell disorders but differ in how they cause organ damage. In myeloma, malignant plasma cells produce M-proteins that damage bones, kidneys, and blood counts directly. In AL amyloidosis, abnormal plasma cells produce misfolded light chain proteins that deposit as amyloid fibrils in organs — particularly the heart, kidneys, liver, and nerves — causing progressive organ failure. Bortezomib (Bortenat) is used in both conditions — it targets the underlying abnormal plasma cell clone in both diseases. In AL amyloidosis, Bortezomib-based therapy can reduce amyloid-producing plasma cells and halt further organ deposition, though it doesn't reverse existing amyloid deposits. Sydney's haematology teams have expertise in both conditions.
